Sana Biotechnology price target raised to $12 from $9 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Sana Biotechnology (SANA) to $12 from $9 and keeps an Overweight rating on the shares. Based on the recent type one diabetes update, the firm increased its probability of success for SC451 from 15% to 20%. The analyst awaits continued hypoimmune pipeline updates throughout 2025. Morgan Stanley found the UP421 update to be a “clean positive” against the objectives outlined by management, reporting “strong” safety, detectable C-peptide levels post-transplantation, and cell survival through 28 days.